{
  "case_id": "Case_5",
  "model_id": "openai/gpt-4o-mini",
  "content": "{\n    \"primary_diagnosis\": {\n        \"name\": \"Parkinson's Disease\",\n        \"confidence\": 0.85,\n        \"icd_code\": \"G20\",\n        \"reasoning\": \"The combination of tremor, bradykinesia, rigidity, and MRI findings suggests a neurodegenerative disorder consistent with Parkinson's disease.\"\n    },\n    \"differential_diagnoses\": [\n        {\n            \"name\": \"Multiple System Atrophy\",\n            \"confidence\": 0.1,\n            \"icd_code\": \"G12.21\",\n            \"reasoning\": \"Considered due to overlapping symptoms but less likely given the MRI findings.\"\n        },\n        {\n            \"name\": \"Wilson's Disease\",\n            \"confidence\": 0.05,\n            \"icd_code\": \"E83.00\",\n            \"reasoning\": \"Possible due to age and symptoms, but less likely without hepatic symptoms or family history.\"\n        },\n        {\n            \"name\": \"Drug-Induced Parkinsonism\",\n            \"confidence\": 0.05,\n            \"icd_code\": \"G21.0\",\n            \"reasoning\": \"Considered due to potential environmental exposures, but no clear indication of prior medication use.\"\n        }\n    ],\n    \"key_findings\": [\n        \"Progressive neurological symptoms including tremor and rigidity\",\n        \"Subtle signal abnormalities in basal ganglia on MRI\"\n    ],\n    \"diagnostic_tests\": [\n        {\n            \"test\": \"Heavy metal screen\",\n            \"purpose\": \"Rule out exposure to environmental toxins\",\n            \"priority\": \"urgent\"\n        },\n        {\n            \"test\": \"Ceruloplasmin and 24-hour urinary copper\",\n            \"purpose\": \"Rule out Wilson's Disease\",\n            \"priority\": \"routine\"\n        }\n    ],\n    \"management_plan\": {\n        \"immediate_actions\": [\n            \"Schedule neurology consultation\",\n            \"Discuss potential environmental toxin exposure\"\n        ],\n        \"medications\": [\n            {\n                \"drug\": \"Carbidopa-Levodopa\",\n                \"dose\": \"25/100 mg\",\n                \"route\": \"PO\",\n                \"duration\": \"As needed based on symptoms\",\n                \"rationale\": \"First-line treatment for Parkinson's Disease to alleviate symptoms.\"\n            }\n        ],\n        \"monitoring\": [\n            \"Neurological status and symptom progression\",\n            \"Every 3 months\"\n        ],\n        \"consultations\": [\n            {\n                \"specialty\": \"Neurology\",\n                \"urgency\": \"urgent\",\n                \"reason\": \"Need for specialized evaluation and management of potential Parkinson's Disease.\"\n            }\n        ]\n    },\n    \"red_flags\": [\n        \"Rapid progression of symptoms\",\n        \"Development of atypical features (e.g., dysautonomia)\"\n    ],\n    \"patient_education\": [\n        \"Importance of early diagnosis and treatment\",\n        \"Potential environmental factors impacting health\"\n    ],\n    \"follow_up\": {\n        \"timing\": \"Follow up in 3 months\",\n        \"conditions\": \"Any worsening of symptoms or new neurological signs\"\n    },\n    \"confidence_in_assessment\": 0.8,\n    \"uncertainties\": [\n        \"Impact of environmental exposure on symptom presentation\",\n        \"Need for additional testing based on symptom progression\"\n    ]\n}",
  "latency": 14.440325021743774,
  "timestamp": "2025-08-10T01:15:50.990552",
  "cached_at": "2025-08-10T01:15:50.990559"
}